Basilea Pharmaceutica – executive interview

Based in Switzerland, Basilea is commercial-stage biopharmaceutical company focused on anti-infective therapies. The company’s two marketed products are Cresemba, a broad-spectrum antifungal for the treatment of severe, life-threatening fungal infections, available in the US and major European countries (through regional partners including Astellas in the US and Pfizer in most of Europe), and Zevtera, a broad-spectrum antibiotic for the treatment of drug-resistant, gram-positive infections, including methicillin-resistant Staphylococcus aureus, and gram-negative bacterial infections, including Pseudomonas. While global Cresemba sales remain the key revenue driver, we expect additional value to come from the upcoming US launch of Zevtera and the introduction of novel clinical (or late preclinical) stage anti-infective assets in Basilea’s development pipeline.

In this video, Basilea CEO David Veitch provides an update on the company’s refocused strategy, development pipeline and key catalysts.